<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2560">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356950</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC-I/2020/JCG-01</org_study_id>
    <nct_id>NCT04356950</nct_id>
  </id_info>
  <brief_title>Analysis of the Coagulopathy Developed by COVID-19 Infected Patients</brief_title>
  <acronym>COVID-TGT</acronym>
  <official_title>Analysis of the Coagulopathy Developed by COVID-19 Infected Patients: Thrombin Generation Potential in COVID-19 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increased D-dimers at admission of COVID-19 infected patients entering hospital due to a
      severe disease is a risk factor for death. Understanding this acquired coagulopathy is a
      prerequisite before specific interventional studies. The study investigators aim to apply a
      normalized and automated thrombin generation test (TGT), developed for testing the thrombotic
      risk (triggered by 5 pM Tissue Factor, with a purified thrombomodulin (TM) challenge) and to
      study its association with survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Accumulating data describe, in COVID-19 severely infected patients necessitating hospitalized
      medical support, the development of an acquired coagulopathy, from a sepsis-induced
      coagulopathy to an overt-DIC, which is a strong risk factor for death. Understanding this
      coagulopathy is a prerequisite before specific interventional studies. Conventional
      coagulation tests, like prothrombin time PT and aPTT, only reflect 5% of the total thrombin
      generation and are insensitive to the patients' natural anticoagulants. The investigators
      thus wish to analyze the coagulopathy of SARS-CoV-2 using a global analytical test reflecting
      the full complexity of thrombin generation then inhibition, the thrombin generation test
      (TGT), in its version designed to analyze the thrombotic risk (initiation by an intermediate
      concentration of human Tissue: 5 pM), in its fully automated and standardized technical
      version. This test analyzes not only the generation of thrombin and its various informative
      phases (initiation phase, propagation phase culminating at the peak of formation, inhibition
      phase with natural anticoagulants) but also the capacity for an exogenous addition of
      purified thrombomodulin (TM), which quantifies the anticoagulant activity of the patient's
      protein C activated by thrombin, to inhibit this generation of thrombin.

      The aim is to assay this TGT version in a centralized way, on the patients' plasma obtained
      at hospital admission, just after checking the positive COVID-19 testing , together with the
      traditional blood tests including platelet counts, PT, D-dimers (DDi) and soluble fibrin
      monomers (FMs). The various quantitative biological parameters describing the results of the
      TGT assay, together with relevant covariates, will be tested using multivariate analysis for
      their capacity to be risk factors for clinically-relevant qualitative outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>28-day survival rate</measure>
    <time_frame>1 month</time_frame>
    <description>Death yes/no during hopstilization, 28 days after admittence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute thrombin generation test latent period</measure>
    <time_frame>Day 0</time_frame>
    <description>Seconds; without (TM-) and with (TM+) purified thrombomodulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative thrombin generation test latent period compared to reference plasma</measure>
    <time_frame>Day 0</time_frame>
    <description>%; without (TM-) and with (TM+) purified thrombomodulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute thrombin generation test initial velocity</measure>
    <time_frame>Day 0</time_frame>
    <description>nmol/s; without (TM-) and with (TM+) purified thrombomodulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative thrombin generation test initial velocity compared to reference plasma</measure>
    <time_frame>Day 0</time_frame>
    <description>%; without (TM-) and with (TM+) purified thrombomodulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative thrombin generation test peak thrombin compared to reference plasma</measure>
    <time_frame>Day 0</time_frame>
    <description>%; without (TM-) and with (TM+) purified thrombomodulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute thrombin generation test peak thrombin</measure>
    <time_frame>Day 0</time_frame>
    <description>nmol/L; without (TM-) and with (TM+) purified thrombomodulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute thrombin generation test peak thrombin time</measure>
    <time_frame>Day 0</time_frame>
    <description>Seconds; without (TM-) and with (TM+) purified thrombomodulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative thrombin generation test peak thrombin time compared to reference plasma</measure>
    <time_frame>Day 0</time_frame>
    <description>%; without (TM-) and with (TM+) purified thrombomodulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute thrombin generation test total thrombin generation time</measure>
    <time_frame>Day 0</time_frame>
    <description>seconds; without (TM-) and with (TM+) purified thrombomodulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative thrombin generation test total thrombin generation time compared to reference plasma</measure>
    <time_frame>Day 0</time_frame>
    <description>%; without (TM-) and with (TM+) purified thrombomodulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute thrombin generation test endogenous thrombin potential</measure>
    <time_frame>Day 0</time_frame>
    <description>Seconds; without (TM-) and with (TM+) purified thrombomodulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative thrombin generation test endogenous thrombin potential compared to reference plasma</measure>
    <time_frame>Day 0</time_frame>
    <description>%; without (TM-) and with (TM+) purified thrombomodulin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-month survival rate</measure>
    <time_frame>3 months</time_frame>
    <description>Death yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfer to intensive care unit during hospitalization</measure>
    <time_frame>3 months</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombotic complication during hospitalization</measure>
    <time_frame>3 months</time_frame>
    <description>Yes/no (deep vein thrombosis, pulmonary embolism, atherothrombosis flare, arterial thrombosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of D-dimers</measure>
    <time_frame>Day 0</time_frame>
    <description>µg / L, assayed by automated enzyme linked fluorescent assay (Vidas® D-dimers Exclusion ™ II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of soluble fibrin monomers</measure>
    <time_frame>Day 0</time_frame>
    <description>mg / L, measured by automated immunoagglutination (STA®-Liatest® FM)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Sepsis</condition>
  <condition>Blood Coagulation Disorders</condition>
  <condition>Thrombin</condition>
  <condition>Disseminated Intravascular Coagulation</condition>
  <condition>COVID-19</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Thrombin generation test assay</intervention_name>
    <description>lag time, initial velocity, time-to-peak, thrombin peak, total thrombin generation time, extrinsic thrombin potential (ETP). Crude quantitative values and relative values (%, by reference to the one obtained with an invariant reference plasma). Both without the addition of purified thrombomodulin (TM-) and with the addition of purified thrombomodulin (TM+). The ability of TM to inhibit thrombin generation will be calculated as follows: [ETP (%)(TM+) / ETP (%)(TM-)].</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fibrin generation markers assays</intervention_name>
    <description>D-dimers (coagulation plus fibrinolysis), soluble fibrin monomers (coagulation only)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients hospitalized for SARS-CoV-2 infection with symptomatology / severity
        requiring hospital treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with SARS-CoV-2 infection (confirmed by positive PCR test) entering
             hospitalization with or without resuscitation

          -  The patient (or their carer) must have given their free and informed consent and
             signed the consent form

          -  The patient must be a member or beneficiary of a health insurance plan

        Exclusion Criteria:

          -  Pregnant or breastfeeding patient

          -  It is impossible to give the subject informed information

          -  The patient is under safeguard of justice or state guardianship

          -  Thrombotic events during treatment: flare-up of venous thromboembolism, flare-up of
             atherothrombosis.

          -  Long-term anticoagulant treatment (anti-vitamin K, direct oral anticoagulant).

          -  Chronic anti-aggregation treatment.

          -  Pre-existing constitutive or acquired known coagulation pathology: hemorrhagic
             diseases (thrombocytopenia, thrombocytopathy, hemophilia, von Willebrand's disease,
             hemorrhagiparous factor deficiency), and for thrombophilia (deficits in antithrombin,
             protein C or S , Factor V Leiden or Prothrombin 20201A mutation).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christophe Gris</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Christophe Gris</last_name>
    <phone>04 66 68 32 11</phone>
    <email>jean.christophe.gris@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles Cazenave</last_name>
      <phone>05.56.79.56.79</phone>
      <email>charles.cazenave@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Charles Cazenave</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-François Faucher</last_name>
      <phone>05.55.05.66.44</phone>
      <email>jean-francois.faucher@unilim.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-François Faucher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle Quere</last_name>
      <phone>04.67.33.70.28</phone>
      <email>i-quere@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Quere</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent Le Moing</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kada Klouche</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Christophe Gris</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Albert Sotto</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier Laureillard</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Lechiche</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudine Barbuat</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marc Mauboussin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Loubet</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Yves Lefrant</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Muller</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saber D Barbar</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire Roger</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonia Perez Martin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coagulation</keyword>
  <keyword>survival</keyword>
  <keyword>thrombin generation test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Disseminated Intravascular Coagulation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

